Such approaches could help standardize risk stratification and improve reproducibility across experts, supporting the MTB in distinguishing lesions with intermediate biological potential, such as atypical Spitz tumors or BAP1-inactivated melanocytic tumors, from true melanomas [15,87]. The gene discussed is BAP1; the disease is melanoma.